BE Study of Two Formulations of Rivaroxaban 2.5 mg in Healthy Subjects
Status:
Completed
Trial end date:
2020-02-14
Target enrollment:
Participant gender:
Summary
The objective of this study was to compare the pharmacokinetic profiles and bioequivalence of
rivaroxaban after a single oral dose of rivaroxaban 2.5 mg tablet in healthy Korean subjects.